Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model

BACKGROUND: The short-term efficacy of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD) has been demonstrated across several phase 3 trials, while the ADPKD Outcomes Model (ADPKD-OM) represents a validated approach to predict natural disease progression over a lifetime...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:BMC Nephrol
Main Authors: Bennett, Hayley, McEwan, Phil, Hamilton, Karina, O’Reilly, Karl
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2019
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6480528/
https://ncbi.nlm.nih.gov/pubmed/31014270
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12882-019-1290-5
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares